

**DRAFT COPY - DO NOT MAIL**

APPL NO.	FILING OR 371(c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	TOT CLMS	IND CLMS
10/583,419	09/28/2007	1614	1030	65507(52059)	20	1

21874  
EDWARDS ANGELL PALMER & DODGE LLP  
P.O. BOX 55874  
BOSTON, MA 02205

CONFIRMATION NO. 3702

**FILING RECEIPT****Applicant(s)**

Christian Hubschwerlen, Durmenach, FRANCE;  
Jean-Luc Specklin, Kembs-Schaeferhof, FRANCE;  
Daniel Baeschlin, Arlesheim, SWITZERLAND;  
Christine Schmitt, Kunheim, FRANCE;  
Stefan Muller, Oberentfelden, SWITZERLAND;  
Michael W. Cappi, Munchen, GERMANY;

**Assignment For Published Patent Application**

Morphochem Aktiengesellschaft Fur Kombinatorische, Munchen, GERMANY

**Power of Attorney:** The patent practitioners associated with Customer Number 21874.

**Domestic Priority data as claimed by applicant**

This application is a 371 of PCT/EP04/14500 12/20/2004  
which claims benefit of 60/530,822 12/18/2003

**Foreign Applications**

EUROPEAN PATENT OFFICE (EPO) 04001506.7 01/23/2004

**If Required, Foreign Filing License Granted:** 10/24/2007

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US10/583,419**

**Projected Publication Date:** 01/31/2008

**Non-Publication Request:** No

**Early Publication Request:** No

**Title**

Oxazolidinone-Quinolone Hybrid Antibiotics

**Preliminary Class**

514

---

**DRAFT COPY - DO NOT MAIL**